Comments
Chennai-based Orchid Pharmaceuticals has received the final approval from the United States Food and Drug Administration for Rasagiline generic formulation, which is used for the treatment of idiopathic Parkinson’s disease.
The company informed the Bombay Stock Exchange that the product is a first-to-file application with shared 180-day exclusivity for Orchid.
With the launch the new product between January and March 2017, the company hopes to garner decent market share in the generic drug market.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.